<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918967</url>
  </required_header>
  <id_info>
    <org_study_id>CT-G20 1.1</org_study_id>
    <nct_id>NCT03918967</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants</brief_title>
  <official_title>A Two-segment Phase I, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G11 and CT-G20 in Healthy Volunteers (Part 1 and Part 2) and Open Label, Balanced, Randomized, Two-period, Two-Sequence Crossover Study to Assess the Effect of Food on the Pharmacokinetics of CT-G20 in Healthy Volunteers (Part 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish safety, tolerability, pharmacokinetics and
      pharmacodynamics of CT-G20 or CT-11 and to evaluate potential effect of food on
      pharmacokinetics of CT-G20 in human participants. It will be conducted in three parts, as
      described below:

        -  Part I will be a randomized, double-blind, placebo-controlled, sequential, single
           ascending dose study.

        -  Part II will be a randomized, double-blind, placebo-controlled, sequential, multiple
           ascending dose study.

        -  Part III will be a randomized, open-label, balanced, two-period, two-sequence crossover,
           food effect study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Actual">June 6, 2020</completion_date>
  <primary_completion_date type="Actual">June 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events including serious Adverse events (Part I, Part II)</measure>
    <time_frame>46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect as assessed by : PK parameters including Area under the concentration-time curve (AUC) and Maximum observed concentration (Cmax) (Part III)</measure>
    <time_frame>Up to 48 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: QT interval of ECG</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: QTcF of ECG</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: blood pressure of Vital signs</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: pulse rate of Vital signs</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: body temperature of Vital signs</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: hematology of Clinical laboratory tests</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters as assessed by: clinical chemistry</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters as assessed by : Area under the concentration-time curve (AUC)</measure>
    <time_frame>13 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters as assessed by : Maximum observed concentration (Cmax)</measure>
    <time_frame>13 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters as assessed by : Time to Cmax (tmax)</measure>
    <time_frame>13 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters as assessed by : Terminal half-life time (t1/2)</measure>
    <time_frame>13 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameters as assessed by : Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>17 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CT-G11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-G11 Experimental Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-G20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CT-G20 Experimental Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-G11 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-G20 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-G11</intervention_name>
    <description>oral tablet of CT-G11 Experimental Drug</description>
    <arm_group_label>CT-G11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-G20</intervention_name>
    <description>oral tablet of CT-G20 Experimental Drug</description>
    <arm_group_label>CT-G20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-G11 Placebo</intervention_name>
    <description>oral tablet of Placebo</description>
    <arm_group_label>CT-G11 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-G20 Placebo</intervention_name>
    <description>oral tablet of Placebo</description>
    <arm_group_label>CT-G20 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) ≥18.0 and ≤30.0 kg/m2

        Exclusion Criteria:

          -  Clinically significant allergic reactions

          -  Gastrointestinal, renal, hematological, metabolic, neurologic or pulmonary diseases
             classified as significant by the Investigator

          -  Hepatic dysfunction upper limit of normal laboratory range

          -  Cardiac history or presence

          -  History or any concomitant active malignancy

          -  A known infection with human immunodeficiency virus, hepatitis B virus (HBV) or
             hepatitis C virus (HCV)

          -  Inherited bleeding diathesis or coagulopathy with the risk of bleeding

          -  Hemoptysis, thrombotic or hemorrhagic event

          -  Cerebral vascular accident, transient ischemic attack, or subarachnoid hemorrhage

          -  History and/or sign/symptoms of abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess

          -  Lactose intolerance (lactase deficiency) and glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>June 7, 2020</last_update_submitted>
  <last_update_submitted_qc>June 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

